Navigation Links
Perdue Kidd & Vickery Wins First Humira Trial - Abbott Laboratories To Pay $2.24 Million
Date:5/9/2013

CHICAGO, May 9, 2013 /PRNewswire/ -- Today, a Cook County jury entered a verdict finding Abbott Laboratories negligent and ordering it to pay $2,244,063.20 to Plaintiff Milton Tietz on behalf of his wife, Delores Tietz . The court entered judgment in that sum, plus costs, in favor of the Plaintiff.  This is the first Humira lawsuit filed against Abbott to go to trial.

"Humira has dangerous side effects and Abbott was negligent regarding them.  Justice has been done," said Tietz attorney Andy Vickery of Perdue Kidd & Vickery.

"We are honored that a jury of twelve people looked at the evidence and agreed that Abbott failed to do what the law requires," said Tietz attorney Jim M. Perdue, Jr.    

Delores Tietz was prescribed Humira, a TNF Blocker, for rheumatoid arthritis in October 2009 and took the drug for close to seven months, before almost dying. In early May 2010, Delores began experiencing chest pain and fevers.  Her illness went undiagnosed for weeks, and her family was told it was probable that she would not survive.  Finally, doctors diagnosed her with Humira-induced disseminated histoplasmosis, a severe, life-threatening infection. 

The FDA issued an alert in September 2008 to all manufacturers of TNF blockers, including Abbott Laboratories, to provide new information to the medical community about the risks of unrecognized, drug-induced histoplasmosis.  Abbott failed to send a letter directly to physicians warning of the danger until May 17, 2010, 20 months after the initial FDA alert and 10 days after Mrs. Tietz was hospitalized.  The jury found that Abbott was negligent for not taking reasonable measures to make sure Delores' doctors had a high index of suspicion for histoplasmosis. 

Milton Tietz is represented by Jim M. Perdue Jr. , Arnold Anderson Vickery and Fred Shepherd of Perdue Kidd & Vickery, and Gary D. McCallister of Gary D. McCallister & Associates LLC.

Perdue Kidd & Vickery is a national law firm of Personal Injury and Drug Injury Trial Lawyers.  The firm represents individuals and businesses across the country who have been harmed personally and financially.  Perdue Kidd & Vickery is based in Houston, Texas. For more information about Perdue Kidd & Vickery, visit www.perduekiddvickery.com or call 713-520-2500.    


'/>"/>
SOURCE Perdue Kidd & Vickery
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
2. Smith & Nephew launches revolutionary open-architecture suture anchor for rotator cuff repair with greater pullout strength than competitors[i]
3. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
4. Biopharma M&A Trends Hold Steady, But Deals Declined in 2011
5. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
8. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
9. Axis Global Logistics Names Mr. Thomas Brennan, Vice President Strategic Accounts & Life Sciences
10. The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Gen-Probe Incorporated in Connection with the Sale of the Company to Hologic, Inc.
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/18/2017)... , Sept. 18, 2017 EpiVax, ... of bioinformatics and immune engineering, today announced ... influenza A (H7N9) vaccine. ... to seasonal influenza and presents a challenge ... prior exposure to be effective. Using state-of-the-art ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the ... a year. In some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, ... retirement havens have extremely low property-tax rates, which contributes to the relatively lower ...
Breaking Medicine News(10 mins):